EWA
ALNY icon

EP Wealth Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

EP Wealth Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$238K Buy
791
+99
+14% +$29.9K ﹤0.01% 1420
2026
Q1 		$229K Buy
692
+21
+3% +$7.15K ﹤0.01% 1329
2025
Q4 		$267K Buy
+671
New +$297K ﹤0.01% 1202
2025
Q2 		$233K Sell
713
-285
-29% -$78.9K ﹤0.01% 1164
2025
Q1 		$269K Buy
+998
New +$256K ﹤0.01% 965
2024
Q4 		– Sell
-732
Closed -$201K – 1239
2024
Q3 		$201K Buy
+732
New +$191K ﹤0.01% 1045
2023
Q4 		– Sell
-1,177
Closed -$208K – 816
2023
Q3 		$208K Buy
1,177
+71
+6% +$13.5K ﹤0.01% 658
2023
Q2 		$225K Hold
1,106
– – ﹤0.01% 627
2023
Q1 		$222K Sell
1,106
-10
-0.9% -$2.1K ﹤0.01% 556
2022
Q4 		$265K Buy
+1,116
New +$238K ﹤0.01% 492

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EP Wealth Advisors's ALNY Position: Q2 2026 in Review

EP Wealth Advisors increased its Alnylam Pharmaceuticals (ALNY) stake by 14% in Q2 2026, buying an estimated $29.9K and bringing the position to 791 shares worth $238K. The position accounts for ﹤0.01% of the portfolio, ranked #1420.

EP Wealth Advisors first reported a position in ALNY in Q4 2022 and has held it in 10 quarters since. The position peaked at $269K in Q1 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • EP Wealth Advisors held 791 shares of Alnylam Pharmaceuticals worth $238K as of Q2 2026.
  • EP Wealth Advisors bought 99 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $29.9K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of EP Wealth Advisors's portfolio in Q2 2026, its #1420 holding.
  • EP Wealth Advisors first reported a position in Alnylam Pharmaceuticals in Q4 2022 and has held it in 10 quarters since.
  • EP Wealth Advisors's Alnylam Pharmaceuticals position peaked at $269K in Q1 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on EP Wealth Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.